Propeller Health is to enter into to a research and development collaboration with pharmaceutical manufacturer GlaxoSmithKline to test a custom sensor for the companies Ellipta inhaler for COPD. GSK will conduct a number of studies of patients with COPD, monitoring the patient's adherence remotely with help from the sensors, which will provide greater insights into how patients interact with their inhalers, and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes. The company has also announced that it plans on developing an app called Propel's Smart Patient Experience (SPE) in partnership with the University of California, San Francisco (UCSF)
Propeller Health is to enter into to a research and development collaboration with pharmaceutical manufacturer GlaxoSmithKline to test a custom sensor for the companies Ellipta inhaler for COPD. GSK will conduct a number of studies of patients with COPD, monitoring the patient's adherence remotely with help from the sensors, which will provide greater insights into how patients interact with their inhalers, and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes. Propeller's monitoring system is becoming increasingly widely used in the US healthcare sector, with over 35 commercial programmes covering the technology.